Young G P, Nagy G S, Myren J, Kronborg I J, Logan K R, Reed P I, Hopper J L
Scand J Gastroenterol. 1986 Nov;21(9):1098-104. doi: 10.3109/00365528608996428.
Twenty-nine patients were treated with a carbenoxolone/antacid/alginate preparation (Pyrogastrone) and 30 with antacid/alginate alone four times each day for 8 weeks, in a double-blind study, to ascertain the value of carbenoxolone in the treatment of patients with endoscopically confirmed reflux oesophagitis. Symptom review every 2 weeks and endoscopic findings every 4 weeks were converted to a 6-point grading system to facilitate statistical comparison, using a stochastic model for predicting the rate of change in grades during treatment. Carbenoxolone-treated patients showed an 82% improvement in symptom grades over 8 weeks and improved 50% faster (P less than 0.01) than did control patients, who showed a 63% improvement. Endoscopic improvement was not significantly different in the first 4 weeks, although healing was better maintained in carbenoxolone-treated patients during the second 4 weeks (P less than 0.05). At the low doses used (5 X 20 mg daily) no significant side effects of carbenoxolone were encountered. Pyrogastrone should be considered as a therapeutic alternative in patients who fail to respond to routine management with antacids.
在一项双盲研究中，29例患者接受了甘珀酸/抗酸剂/藻酸盐制剂（胃溃宁）治疗，30例患者仅接受抗酸剂/藻酸盐治疗，均为每日4次，持续8周，以确定甘珀酸在治疗经内镜确诊的反流性食管炎患者中的价值。每2周进行症状复查，每4周进行内镜检查，结果转换为6分制分级系统，以便于统计比较，采用随机模型预测治疗期间分级的变化率。接受甘珀酸治疗的患者在8周内症状分级改善了82%，改善速度比对照组患者快50%（P<0.01），对照组患者改善了63%。在最初4周内，内镜改善情况无显著差异，尽管在随后4周内，接受甘珀酸治疗的患者愈合情况保持得更好（P<0.05）。在使用的低剂量（每日5×20mg）下，未发现甘珀酸有明显副作用。对于对抗酸剂常规治疗无反应的患者，应考虑将胃溃宁作为一种治疗选择。
